Merck & Co., Inc. (BVL:MRK)

Market Cap	909.09B
Revenue (ttm)	222.71B
Net Income (ttm)	65.99B
Shares Out	n/a
EPS (ttm)	26.20
PE Ratio	13.78
Forward PE	11.89
Dividend	11.57 (10.85%)
Ex-Dividend Date	Dec 15, 2025

Volume	272
Average Volume	49
Open	106.64
Previous Close	107.00
Day's Range	106.64 - 106.64
52-Week Range	73.98 - 107.00
Beta	n/a
RSI	74.87
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Pharmaceutical Preparations
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD